Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22982172 | 0.92 | LGALS3 (0.61) | LGALS3LGALS1 | |
| SCHEMBL22981168 | 0.92 | LGALS3 (0.60) | LGALS3LGALS1 | |
| SCHEMBL22982002 | 0.91 | LGALS3 (0.70) | LGALS3LGALS1 | |
| SCHEMBL22247034 | 0.88 | LGALS3 (0.72) | LGALS3LGALS1 | |
| SCHEMBL26727629 | 0.88 | LGALS3 (0.66) | LGALS3LGALS1 | |
| SCHEMBL22542393 | 0.86 | LGALS3 (0.72) | LGALS3LGALS1 | |
| SCHEMBL22247258 | 0.84 | LGALS3 (0.75) | LGALS3LGALS1 | |
| SCHEMBL17964039 | 0.84 | LGALS3 (0.75) | LGALS3LGALS1 | |
| SCHEMBL17993057 | 0.84 | LGALS3 (0.75) | LGALS3LGALS1 | |
| SCHEMBL23042144 | 0.83 | LGALS3 (0.71) | LGALS3LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304902-B2 | Hydroxyheterocycloalkane-carbamoyl derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-20 | — | — | US | disclosed |
| US-12291520-B2 | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-06 | — | — | US | disclosed |
| US-12291519-B2 | 2-hydroxycycloalkane-1-carbamoyl | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-06 | — | — | US | disclosed |
| EP-4291556-B1 | HYDROXYHETEROCYCLOALKANE-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-4013751-B1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-01-22 | — | — | EP | disclosed |
| US-20240124427-A1 | HYDROXYHETEROCYCLOALKANE-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-04-18 | — | — | US | disclosed |
| EP-4291556-A1 | HYDROXYHETEROCYCLOALKANE-CARBAMOYL DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20230348442-A1 | GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230348442-A1 | GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230348442-A1 | GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-11-02 | — | — | US | disclosed |
| CN-116806219-A | Hydroxy-heterocylic-carbamoyl derivatives | 爱杜西亚药品有限公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-4237419-A1 | GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1 -CARBAMOYL DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2023-09-06 | — | — | EP | disclosed |
| US-20220324847-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-13 | — | — | US | disclosed |
| WO-2022171594-A1 | HYDROXYHETEROCYCLOALKANE-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-08-18 | — | — | WO | disclosed |
| EP-4013751-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022090544-A1 | GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1 -CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-05 | — | — | WO | disclosed |
| CN-114269737-A | 2-hydroxycycloalkane-1-carbamoyl derivatives | 爱杜西亚药品有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021028570-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348442-A1 | GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885 |
| US-12291520-B2 | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885 |
| US-12291519-B2 | 2-hydroxycycloalkane-1-carbamoyl | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885 |
| US-12304902-B2 | Hydroxyheterocycloalkane-carbamoyl derivatives | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885 |
| US-20240124427-A1 | HYDROXYHETEROCYCLOALKANE-CARBAMOYL DERIVATIVES | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885 |
| US-20220324847-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.